Alkermes Pharma Ireland Limited

Otsuka Pharmaceutical Company, Limited

Peter J Weiden

Marjie L Hard

Lisa L Von Moltke

Ainslie Hatch

Ruth Ross

John P Docherty

Dawn I Velligan

The present invention relates to methods of treating schizophrenia using a combination of aripiprazole, aripiprazole lauroxil, and a nanoparticle dispersion of aripiprazole lauroxil.

Aripiprazole dosing strategy

In some embodiments, a system includes an ingestible signal generator coupled to a medication and configured to generate a body-transmissible signal upon ingestion by a user. The system also includes a receiver, the receiver including a sensor configured to detect the body-transmissible signal, the receiver configured to generate and wirelessly transmit a sensor signal based on the body-transmissible signal. The system also includes a user device. A processor of the user device is configured to wirelessly monitor the sensor for the sensor signal and, in response to not receiving the sensor signal within a predetermined time period, generate a notification. The processor is further configured to send a signal to present the notification and receive a response to the notification from the user. The processor is also configured to identify at least one trend associated with the sensor signal and the medication, and perform an action based thereon.

Systems, devices, and methods for ingestible event sensing and analysis

Growing community of inventors

Newton, MA, United States of America

Peter J Weiden